Developing software to predict how well PROTACs can degrade target proteins
Algorithm and software for predicting the structure and degrading efficiency of PROTACs
['FUNDING_SBIR_1'] · ACPHARIS, INC. · NIH-11008026
This study is working on a new computer program that helps scientists design special molecules called PROTACs, which can help get rid of harmful proteins in the body, potentially leading to better treatments for diseases caused by protein issues.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ACPHARIS, INC. (nih funded) |
| Locations | 1 site (HOLLISTON, UNITED STATES) |
| Trial ID | NIH-11008026 on ClinicalTrials.gov |
What this research studies
This research focuses on creating an algorithm and software that can accurately predict the structure and effectiveness of PROTACs, which are innovative molecules designed to degrade specific proteins in the body. By connecting a target protein to an E3 ubiquitin ligase, PROTACs can initiate the degradation of unwanted proteins, potentially leading to new treatments for various diseases. The project aims to improve the design of PROTACs by generating models of the interactions between these molecules and their targets, making it easier for researchers to develop effective therapies. Patients may benefit from this research as it could lead to more targeted and effective treatments for conditions related to protein misregulation.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with conditions that involve protein misregulation, such as certain cancers or neurodegenerative diseases.
Not a fit: Patients with conditions unrelated to protein degradation or those who do not respond to PROTAC-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for diseases caused by the malfunction of specific proteins.
How similar studies have performed: Other research has shown promise in using computational tools for drug design, indicating that this approach could be effective.
Where this research is happening
HOLLISTON, UNITED STATES
- ACPHARIS, INC. — HOLLISTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BEGLOV, DMITRI — ACPHARIS, INC.
- Study coordinator: BEGLOV, DMITRI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.